

BLOOD LOSS AND PROLONGED AIR LEAK





REDUCTION BY APPLYING TENATAC® GELATIN PATCH AFTER MAJOR PULMONARY MINIMAL-INVASIVE RESECTION

RIVERA CAROLINE¹, PERROT CYRIL², MAZERES FLORENCE¹ AND RIVE ELODIE²

¹ Department of Thoracic Surgery, Bayonne Hospital, Bayonne, France; ² Medical Advices Consulting SARLs, Lëtzebuerg, Luxembourg



INTRODUCTION: Reduction of bleeding and **prolonged air leak** (PAL >5 days) following major lung resection remains a challenge. Hemostasis and aerostasis devices can facilitate earlier pleural de-drainage and fast-track. Our objectives were to evaluate the efficacy of **TenaTac®** (100% pharmaceutical **gelatin device**) in reducing bleeding after major lung resection and in reducing PAL.

MATERIEL & METHODS: This monocentric retrospective **case-control study**, using prospectively collected data, includes 60 patients who underwent, between 2022 and 2024, minimally invasive **robot-assisted lobectomy** or segmentectomy: 30 with TenaTac® vs. 30 with other devices. Data were extracted from **Epithor**, our national database, with ethics committee validation.



The application of TenaTac® is characterized by a gel-like transformation, which results in a sealing effect.

RESULTS: Patients characteristics, Index of PAL (IPAL) and surgical procedures were similar in the two groups (NS). TenaTac® hemostatic benefit was comparable to other devices (p=0.43). **PAL rate** was **significantly lower with TenaTac®** (3%) than for controls (37%) (p=0.0004). **Postoperative air leakage duration** was **significantly shorter in TenaTac® group** than in control group (2.23±2.57 vs. 4.23±3.87 days, p=0.01). **Mean drainage duration** and **length of stay** were **reduced with TenaTac® by 36 hours**. No significant difference was observed between the two groups in terms of morbidity (90-day postoperative complications classified as Clavien-Dindo grade>II, p=0.30), readmission rates (nil) or 90-day mortality (no deaths).



90-day follow-up with TenaTac®



Readmissions
Serious adverse events
Deaths

CONCLUSION: Numerous hemostatic or aerostatic devices have been previously evaluated without achieving consensus in the prevention of PAL. Thanks to its characteristics of absorbable adherent gelatin, **TenaTac® significantly reduces the incidence of PAL**. Its easy handling and application make it an optimal subject for controlled prospective evaluation.